Infectious disease specialists (I am not one)make a distinction between TB “infection” and TB “disease.” Infection is defined as having a positive skin test to an intradermal injection of “tuberculin,” or “purified protein derivative [PPD].” This detects whether or not you have a cell-mediated antigenic response to PPD. A postive response indicates a prior “exposure” to Mycobacterium tuberculosis [MTB], the bacterium that causes TB. It is important to realize that people with deficits in cell-mediated immunity (i.e. those with AIDS, transplant recipents, etc.)may be infected with MTB and not have a positive PPD skin test.
TB “disease” involves having symptoms of TB (cough, fevers/chills/night sweats, weight loss, and symptoms of pneumonia). Most important, from the public health standpoint, TB disease implies that MTB is active and contagious. Contagious TB is spread by droplet infection, and contagious patients will shed infectious MTB in their sputum. This may be tested by culturing sputum from suspected patients.
The current recommendations for treating asymptomatic TB infection is to treat for about 6 months with a “prophylactic” regimen of INH. The aim of this is to reduce the risk of developing TB disease at a later date.
For those with TB disease, treatment is with at leats two or three antibiotics, usually INH, rifampin, and something else (PZA, ethambutol, streptomycin, etc.). Such treatment is guided by the results of TB cultures tested for antibiotic sensitivity/resistance.
ALL of the anti-tubercular drugs are potentially hepatotoxic, so treatment must be closely monitored.
In the USA, TB was becoming “extinct” until the late 1980’s. There has been a resurgence of TB in the US, which may be blamed upon various things, such as homelessness and AIDS. However, the main culprit is probably immigration to the US of immigrants from areas where TB is endemic, namely ASIA (especially Southeast Asia and the Indian subcontinent), Mexico and Central America, and Eastern Europe.